[1]
Schcolnik-Cabrera, A.; Juarez-Lopez, D.; Duenas-Gonzalez, A. Perspectives on drug repurposing. Curr. Med. Chem., 2020, 28(11), 2085-2099.
[http://dx.doi.org/10.2174/0929867327666200831141337 PMID: 32867630 ]
[http://dx.doi.org/10.2174/0929867327666200831141337 PMID: 32867630 ]
[2]
Abbasi, K.; Razzaghi, P.; Poso, A.; Ghanbari-Ara, S.; Masoudi-Nejad, A. Deep learning in drug target interaction prediction: current and future perspectives. Curr. Med. Chem., 2020, 28(11), 2100-2113.
[http://dx.doi.org/10.2174/0929867327666200907141016 PMID: 32895036]
[http://dx.doi.org/10.2174/0929867327666200907141016 PMID: 32895036]
[3]
Falvo, P.; Orecchioni, S.; Roma, S.; Raveane, A.; Bertolini, F. Drug repurposing in oncology, an attractive opportunity for novel combinatorial regimens. Curr. Med. Chem., 2020, 28(11), 2114-2136.
[http://dx.doi.org/10.2174/0929867327999200817104912 PMID: 33109033]
[http://dx.doi.org/10.2174/0929867327999200817104912 PMID: 33109033]
[4]
Antoszczak, M.; Markowska, A.; Markowska, J.; Huczyński, A. Antidepressants and antipsychotic agents as repurposable oncological drug candidates. Curr. Med. Chem., 2020, 28(11), 2137-2174.
[http://dx.doi.org/10.2174/0929867327666200907141452] [PMID: 32895037]
[http://dx.doi.org/10.2174/0929867327666200907141452] [PMID: 32895037]
[5]
Zhang, Z.; Ji, J.; Liu, H. Drug repurposing in oncology: current evidence and future direction. Curr. Med. Chem., 2020, 28(11), 2175-2194.
[http://dx.doi.org/10.2174/0929867327999200820124111 PMID: 33109032]
[http://dx.doi.org/10.2174/0929867327999200820124111 PMID: 33109032]
[6]
Allegra, A.; Imbesi, C.; Bitto, A.; Ettari, R. Drug repositioning for the treatment of hematologic disease: limits, challenges and future perspectives. Curr. Med. Chem., 2020, 28(11), 2195-2217.
[http://dx.doi.org/10.2174/0929867327999200817102154 PMID: 33138750]
[http://dx.doi.org/10.2174/0929867327999200817102154 PMID: 33138750]
[7]
Nehme, R.; Hallal, R.; El Dor, M.; Kobeissy, F.; Gouilleux, F.; Mazurier, F.; Zibara, K. Repurposing of acriflavine to target chronic myeloid leukemia treatment. Curr. Med. Chem., 2020, 28(11), 2218-2233.
[http://dx.doi.org/10.2174/0929867327666200908114411 PMID: 32900342]
[http://dx.doi.org/10.2174/0929867327666200908114411 PMID: 32900342]
[8]
Paliogiannis, P.; Fois, S.S.; Fois, A.G.; Cossu, A.; Palmieri, G.; Pintus, G. Repurposing anticancer drugs for the treatment of idiopathic pulmonary fibrosis and antifibrotic drugs for the treatment of cancer: state of the art. Curr. Med. Chem., 2020, 28(11), 2234-2247.
[http://dx.doi.org/10.2174/0929867327999200730173748] [PMID: 32748739]
[http://dx.doi.org/10.2174/0929867327999200730173748] [PMID: 32748739]
[9]
Iratni, R.; Ayoub, M.A. Sildenafil in combination therapy against cancer: a literature review. Curr. Med. Chem., 2020, 28(11), 2248-2259.
[http://dx.doi.org/10.2174/0929867327666200730165338 PMID: 32744956]
[http://dx.doi.org/10.2174/0929867327666200730165338 PMID: 32744956]
[10]
Alaaeddine, R.A.; Elzahhar, P.A.; AlZaim, I.; Abou-Kheir, W.; Belal, A.S.F.; El-Yazbi, A.F. The emerging role of COX-2, 15-LOX, and PPARgamma in metabolic diseases and cancer: An introduction to novel multi-target directed ligands (MTDLs). Curr. Med. Chem., 2020, 28(11), 2260-2300.
[http://dx.doi.org/10.2174/0929867327999200820173853] [PMID: 32867639]
[http://dx.doi.org/10.2174/0929867327999200820173853] [PMID: 32867639]
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
17
2